



## What is EURIPID?

EURIPID is a **voluntary and strictly non-profit cooperation** between European countries on building up and maintaining a database with information on **national prices and pricing regulations** of medicinal products in a **standardised format**.

## What is EURIPID's mission?

The mission of EURIPID is to make pricing of pharmaceuticals more transparent. The members of EURIPID believe, that **improving transparency** is a mean to improve patients' **access to affordable medicines**. The **Pharmaceutical Strategy for Europe** states as well that the Commission will foster transparency of price information to help Member States to take better pricing and reimbursement decisions, also considering possible knock-on effects for innovation.

## How is EURIPID organised?

### 1 Board of Participants (BoP)

The BoP takes strategic decisions. The BoP consists of one representative of each participating country or organisation and the members of the Executive Committee, which are not part of the BoP. The chair of the BoP is elected by the participants for three years.


### 2 Executive Committee

The Executive Committee focuses on the operational level. It consists of one representative of each founder (NEAK and GÖG), three elected members of the EURIPID collaboration and a representative of the European Commission (EC)

### 3 Project team

The project team acts on behalf of the members and is responsible for project management, all activities related to smooth operating of the project i.e. carrying out the daily work

## Which countries are members of EURIPID?



## Current chair of the BoP

**Momir Radulović**

Executive Director of the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia (JAZMP)  
His previous work experience includes hospital, community pharmacy, and the pharmaceutical industry.




## Main activities of EURIPID

Data Provision to members of the EURIPID collaboration and researchers



Improve transparency in the field of pharmaceutical pricing and reimbursement



Deepen collaboration between European countries and their competent authorities



## Which information does the database contain?

Continuous price information, partly dating back to 2010



Information on pharmaceutical prices, volumes and the existence of Managed Entry Agreements



Information on pharmaceutical systems from > 26 countries




Additional information can be found here: [www.euripid.eu](http://www.euripid.eu)

This information leaflet was funded by the European Union's Health Programme (2014-2020).



## Milestones of EURIPID

Since its beginning as technical undertaking the EURIPID Collaboration has evolved to be an important player in the field of pricing of medicinal products in Europe.



### Achievements of the EURIPID Collaboration

- Easy to use 24-hour available database with constantly updated price information
- Most comprehensive source on publicly available price records (~30 Mio. data points) which is readily accessible to national authorities for pricing and reimbursement
- The EURIPID collaboration jointly developed with experts from national authorities and stakeholder groups 12 guiding principles on External Price Referencing (EPR)
- The EURIPID team is engaged in various research activities like data analysis for partners or in exploring new fields where EURIPID data can be used
- Channelling discussions on pricing and reimbursement
- Knowledge broker and capacity builder
- EURIPID has been named as a project to support the flagship initiatives to make medicines more affordable under the „Pharmaceutical Strategy for Europe“

The content of this leaflet represents the view of EURIPID consortium members only and is their sole responsibility. It can not be considered to reflect the views of the European Commission and/or the European Health and Digital Executive Agency (HADEA) or any other body established within the remit of the Institutions of the European Union. The European Commission and HADEA do not accept any responsibility for use that may be made of the information it contains.

## Grant-specific milestones of EURIPID

The EURIPID collaboration is funded by an annual contribution fee of the participants. However, to further develop EURIPID, the collaboration applies for public funding. From 2019 until 2022, the EURIPID collaboration has been awarded a grant in the framework of the EU Health Programme.



**Comprehensive information dissemination** to inform the general public and stakeholders about EURIPID and its activities.

- Launch of a public website ([www.euripid.eu](http://www.euripid.eu))
- Regular newsletters to members of the EURIPID Collaboration and subscribers
- Dedicated EU-Health Policy Platform Stakeholder Network

**Feasibility study** on the integration of prices of selected medical devices into the EURIPID database

- How do pricing and reimbursement systems of medical devices in selected European countries work?
- Which price types are available?
- Further discussion on integration was postponed until 2024




**Series of webinars** in the field of pricing/prices of pharmaceuticals

- Altogether > 230 participants
- Balanced presentation of examples from theory and practice
- Covered topics: Pricing policies, Price comparisons & How EURIPID can support decision makers

**Strengthen cooperation** with Public Institutions and stakeholders

- 4 Stakeholder dialogue platforms
- Joint statement with stakeholders
- Cooperation with EUROSTAT on calculating Purchasing Power Parities (PPP) for medicines



### Outlook for the future

- Deepening already existing cooperations (EUROSTAT, OECD)
- Exploring potential cooperation with the WHO
- Further develop the database to better serve the needs of its users (e.g. data extension)
- The EURIPID Collaboration will continue to express interest for relevant EU grants and in view of further developing features in a way to bring value to the users

